Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 900 participants.

Also called NCT04848506

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 900 participants (planned count) (from the registry)
Sponsor
  • Cytokinetics Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04848506
  • EudraCT 2020-003571-17
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Iceland, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT04848506. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-06 (actual); primary completion 2029-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
Acronym
FOREST-HCM
Condition
Symptomatic Hypertrophic Cardiomyopathy (HCM)
Intervention (Drug)
Aficamten (5 - 20 mg)
Lead sponsor
Cytokinetics (class: industry)

Record details

Record id
cardio:ct-nct04848506
Content hash
df6a85e83f0b7d4b3a9f921494736b695b719c30168063f5f53932950ea4be85